FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Kun He(Peking Union Medical College Hospital), W. David McGuinn(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Robert Justice(United States Food and Drug Administration), Anne‐Marie Russell(Birmingham City University), Donna Roscoe(Center for Devices and Radiological Health), Marc R. Theoret(United States Food and Drug Administration), John R. Johnson(Santa Barbara Museum of Natural History), Whitney S. Helms(Center for Drug Evaluation and Research), Maitreyee Hazarika(Center for Drug Evaluation and Research), Justin Earp(United States Food and Drug Administration), Sarah Pope Miksinski(Center for Drug Evaluation and Research), Xiaoping Jiang, Shenghui Tang(Center for Drug Evaluation and Research), Qiang Casey Xu(Center for Drug Evaluation and Research), Amy E. McKee(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Qi Liu(Southwest University), Yang‐Min Ning(United States Food and Drug Administration), Jeanne Fourie Zirkelbach(United States Food and Drug Administration)
Cited by 215
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k